|
KMID : 1161420120150111038
|
|
Journal of Medicinal Food
2012 Volume.15 No. 11 p.1038 ~ p.1044
|
|
|
Effects of Ecklonia cava Polyphenol in Individuals with Hypercholesterolemia: A Pilot Study
|
|
Lee Dong-Hyeon
Park Mi-Yeon
Shim Byung-Joo
Youn Ho-Joong
Hwang Hye-Jeong
Shin Hyeon-Cheol
Jeon Hui-Kyung
|
|
|
Abstract
|
|
|
|
We evaluated the efficacy and safety of Ecklonia cava polyphenol (Seapolynol™, a polyphenol antioxidant and anti-inflammatory agent purified from E. cava) during a 12-week treatment period (400?mg orally once daily) in individuals with hypercholesterolemia and performed subgroup analysis for metabolic syndrome (MetS). As a noncomparative study, forty-six individuals (M:F=22:24, mean age=54±11 years) with fasting total cholesterol concentration >240?mg/dL or low-density lipoprotein cholesterol (LDL-C) concentration >130?mg/dL were enrolled. Hip circumference (100±7?cm vs. 98±7?cm, P<.01), total cholesterol (244±25?mg/dL vs. 225±37?mg/dL, P<.01), LDL-C (161±24?mg/dL vs. 146±34?mg/dL, P<.01), and C-reactive protein (2.51±3.55?mg/L vs. 1.37±1.32?mg/L, P<.05) were significantly decreased without significant adverse effect. A differential assessment according to the presence [MetS(+) group, n=18] and absence [MetS(?) group, n=28] of MetS showed that HbA1c decreased significantly following 12-week Seapolynol treatment in the MetS(+) compared with the MetS(?) group (?0.3%±0.5% vs. 0.1%±0.3%, P<.01). In conclusion, although our results showed that Seapolynol treatment is effective and safe without significant adverse events or abnormal laboratory findings during a 12-week period in individuals with hypercholesterolemia, more research in a larger population with a longer-term follow-up period in a randomized placebo-controlled study is needed to confirm the results.
|
|
|
KEYWORD
|
|
|
C-reactive protein, Ecklonia cava polyphenol, hemoglobinA1c, hypercholesterolemia, metabolic syndrome, LDL-cholesterol
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|